CD274 and Miyoshi myopathy: The therapeutic effect of the MAbs targeting PD-1/PD-L1 group was poor and the incidence of adverse events was not reduced or was even higher in comparison with the control or the other two groups, offering a limited therapeutic value to patients with MM.